Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-06-29
DOI
10.1038/s41598-022-14726-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
- (2021) Zohreh Amoozgar et al. Nature Communications
- Immunoactivating the tumor microenvironment enhances immunotherapy as predicted by integrative computational model
- (2020) Aleksander S. Popel PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combining microenvironment normalization strategies to improve cancer immunotherapy
- (2020) Fotios Mpekris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
- (2020) Chiara Caraccio et al. Frontiers in Immunology
- Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology
- (2020) Alison Betts et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities
- (2020) Peter N. Morcos et al. CTS-Clinical and Translational Science
- CAR T cell therapies for patients with multiple myeloma
- (2020) Lekha Mikkilineni et al. Nature Reviews Clinical Oncology
- Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
- (2020) Huilin Ma et al. Journal for ImmunoTherapy of Cancer
- Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
- (2020) Iraj Hosseini et al. npj Systems Biology and Applications
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2019) Moshe Sade-Feldman et al. CELL
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
- (2019) Oleg Milberg et al. Scientific Reports
- Nanobody-based dual epitopes protein identification (DepID) assay for measuring soluble CD38 in plasma of multiple myeloma patients
- (2018) Ting Li et al. ANALYTICA CHIMICA ACTA
- Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity
- (2018) Olivia Campagne et al. CLINICAL CANCER RESEARCH
- Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma
- (2018) Katharina Kriegsmann et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
- (2018) Jinyang Li et al. IMMUNITY
- Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents
- (2018) Xiling Jiang et al. mAbs
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development
- (2018) Patrick M. Glassman et al. Drug Metabolism and Pharmacokinetics
- Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
- (2018) Diego Ellerman METHODS
- Origin and differentiation of human memory CD8 T cells after vaccination
- (2017) Rama S. Akondy et al. NATURE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- BioNetGen 2.2: advances in rule-based modeling
- (2016) Leonard A. Harris et al. BIOINFORMATICS
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
- (2016) Matthias Klinger et al. IMMUNOLOGICAL REVIEWS
- T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
- (2016) Claudia Zelle-Rieser et al. Journal of Hematology & Oncology
- Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
- (2015) M. Al-Hussaini et al. BLOOD
- Bispecific antibodies and their applications
- (2015) Gaowei Fan et al. Journal of Hematology & Oncology
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Bispecific T-cell engagers for cancer immunotherapy
- (2014) Amelia M Huehls et al. IMMUNOLOGY AND CELL BIOLOGY
- T cell responses: naïve to memory and everything in between
- (2013) Nathan D. Pennock et al. ADVANCES IN PHYSIOLOGY EDUCATION
- CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
- (2013) C. Krupka et al. BLOOD
- Selective Activation of Antigen-Experienced T Cells by Anti-CD3 Constrained on Nanoparticles
- (2013) Y.-C. Lo et al. JOURNAL OF IMMUNOLOGY
- An integrated strategy for prediction uncertainty analysis
- (2012) J. Vanlier et al. BIOINFORMATICS
- Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells
- (2012) A. Feldmann et al. JOURNAL OF IMMUNOLOGY
- Overview of the immune response
- (2010) David D. Chaplin JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation
- (2010) Yixin Li et al. Journal of Translational Medicine
- A methodology for performing global uncertainty and sensitivity analysis in systems biology
- (2008) Simeone Marino et al. JOURNAL OF THEORETICAL BIOLOGY
- Conferral of Enhanced Natural Killer Cell Function by KIR3DS1 in Early Human Immunodeficiency Virus Type 1 Infection
- (2008) B. R. Long et al. JOURNAL OF VIROLOGY
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now